Exagen Inc. (XGN) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 10 Buy.
The consensus price target is $13.00 (low: $9.00, high: $15.00), representing an upside of 327.6% from the current price $3.04.
Analysts estimate Earnings Per Share (EPS) of $-0.89 and revenue of $0.06B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.83 vs est $-0.89 (beat +6.6%). 2025: actual $-0.93 vs est $-0.88 (missed -5.7%). Analyst accuracy: 94%.
XGN Stock — 12-Month Price Forecast
$13.00
▲ +327.63% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Exagen Inc., the average price target is $13.00, with a high forecast of $15.00, and a low forecast of $9.00.
The average price target represents a +327.63% change from the last price of $3.04.
Highest Price Target
$15.00
Average Price Target
$13.00
Lowest Price Target
$9.00
XGN Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Exagen Inc. in the past 3 months
EPS Estimates — XGN
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.83
vs Est –$0.89
▲ 7.1% off
2025
Actual –$0.93
vs Est –$0.88
▼ 5.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — XGN
100%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.056B
vs Est $0.055B
▲ 0.3% off
2025
Actual $0.067B
vs Est $0.066B
▲ 0.1% off
Revenue Trend
Moderate revenue growth trend. Analysts forecast revenue contraction ahead.
